| P2093 | author name string | Heidi E Hamm | |
| | John H Cleator | |
| | Qingxia Chen | |
| | Michael Holinstat | |
| | Dana Blakemore | |
| | Nancy E Colowick | |
| | Willie J Hudson | |
| P2860 | cites work | A new role for P-selectin in shear-induced platelet aggregation | Q73108662 |
| | Pathophysiology of platelet thrombin receptors | Q73447376 |
| | Protease-activated receptors differentially regulate human platelet activation through a phosphatidic acid-dependent pathway | Q79411445 |
| | Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation | Q79917817 |
| | Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective | Q24293646 |
| | CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation | Q28118463 |
| | Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial | Q28210574 |
| | Protease-activated receptors in cardiovascular diseases | Q28261926 |
| | Bivalirudin during primary PCI in acute myocardial infarction | Q28281179 |
| | Thrombin signalling and protease-activated receptors | Q29619601 |
| | Rap1b is required for normal platelet function and hemostasis in mice | Q33778323 |
| | Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates | Q33905952 |
| | Thrombin-receptor antagonist vorapaxar in acute coronary syndromes | Q34231934 |
| | New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology | Q34262824 |
| | Vorapaxar in the secondary prevention of atherothrombotic events | Q34263311 |
| | PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation | Q34560212 |
| | Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention | Q34906975 |
| | The evolving role of direct thrombin inhibitors in acute coronary syndromes | Q35088077 |
| | The adhesion molecule P-selectin and cardiovascular disease | Q35601863 |
| | P-selectin in arterial thrombosis | Q35965541 |
| | Protease-activated receptors in hemostasis, thrombosis and vascular biology | Q36230881 |
| | G-protein-coupled receptors as signaling targets for antiplatelet therapy | Q37331201 |
| | Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. | Q37786695 |
| | Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis | Q40310781 |
| | Irreversible platelet activation requires protease-activated receptor 1-mediated signaling to phosphatidylinositol phosphates | Q42265142 |
| | Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention | Q44159298 |
| | Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status | Q44816746 |
| | Synergistic inhibition of platelet aggregation by fibrinogen-related peptides | Q44970734 |
| | Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin. | Q45997448 |
| | Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study | Q46088369 |
| | Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates | Q46443116 |
| | Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial | Q46627427 |
| | Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin | Q46684149 |
| | Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor | Q47295608 |
| | The thrombomodulin-protein C system is essential for the maintenance of pregnancy. | Q52549296 |
| | Protease-activated receptor 4 uses anionic residues to interact with alpha-thrombin in the absence or presence of protease-activated receptor 1. | Q53434074 |
| | Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. | Q55055193 |
| | Prognostic Value of a High On-Clopidogrel Treatment Platelet Reactivity in Bivalirudin Versus Abciximab Treated Non–ST-Segment Elevation Myocardial Infarction Patients | Q60195494 |
| | Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry | Q68160190 |
| P433 | issue | 2 | |
| P304 | page(s) | 209-222 | |
| P577 | publication date | 2013-02-01 | |
| P1433 | published in | Journal of Thrombosis and Thrombolysis | Q15766541 |
| P1476 | title | Dichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation | |
| P478 | volume | 35 | |